$ADPT News

Adaptive Biotechnologies Says NGS-Based ClonoSEQ Test For Measurable Residual Disease Assessment Will Be Included In 33 Presentations Across 2026 ASCO And EHA Congress

Morgan Stanley Maintains Equal-Weight on Adaptive Biotechnologies, Lowers Price Target to $18

Adaptive Biotechnologies Corporation 2026 Q1 - Results - Earnings Call Presentation

JP Morgan Maintains Overweight on Adaptive Biotechnologies, Lowers Price Target to $19

TD Cowen Maintains Buy on Adaptive Biotechnologies, Raises Price Target to $21

Guggenheim Reiterates Buy on Adaptive Biotechnologies, Maintains $21 Price Target

BTIG Reiterates Buy on Adaptive Biotechnologies, Maintains $22 Price Target

Adaptive Biotechnologies (NASDAQ:ADPT) Surges 6% on Q1 Beat and Raised MRD Guidance

Adaptive Biotechnologies (ADPT) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates

Adaptive Biotechnologies Q1 Earnings Call Highlights

Adaptive Biotechnologies Corporation (ADPT) Q1 2026 Earnings Call Transcript

Adaptive Biotechnologies (ADPT) Reports Q1 Loss, Beats Revenue Estimates

Adaptive Biotechnologies Reports First Quarter 2026 Financial Results

Transcript: Adaptive Biotechnologies Q1 2026 Earnings Conference Call

Adaptive Biotechnologies Q1 EPS $(0.13) Beats $(0.17) Estimate, Sales $70.874M Beat $60.850M Estimate

Adaptive Biotechnologies' Chief Operating Officer Sold Over 19,000 Company Shares. Here's What That Means for Investors.

How The Investment Story For Adaptive Biotechnologies (ADPT) Is Shifting With New Street Assumptions

Adaptive Biotechnologies' COO Is Running a Systematic Sell Program — Here's What It Means

Adaptive Biotechnologies: Strong Sequencing, Weak Margin Of Safety

Should You Sell Adaptive Biotechnologies (ADPT) After Its President and COO Sold 57,000 Shares?